Prescription Opiate Abuse Treatment Study (POATS)
Roger Weiss, M.D. Co-Lead Investigator Harvard Medical School McLean Hospital 115 Mill St. Belmont, MA 02478 rweiss@mclean.harvard.edu http://www.mclean.harvard.edu/research/clinicalunit/adatp/ctn.php Walter Ling, Ph.D. Co-Lead Investigator Director, Integrated Substance Abuse Programs, UCLA 11075 Santa Monica Boulevard Suite 225 Los Angeles, CA 90025 lwalter@ix.netcom.com

This is a randomized, two-phase, open-label, multi-center study in outpatient treatment settings.  The main objective of this trial is to identify effective treatment regimen for sublingual Buprenorphine/Naloxone (BUP/NX) in patients dependent on prescription opioids.  The first phase will assess the currently prevailing 1-month detoxification practice.  The second phase will compare the effectiveness of standard medical (BUP/NX) management and medical management (BUP/NX) enhanced by intensive individual drug counseling (IDC) in those patients that were not successful in the previous phase.  The study will involve approximately 672 participants, recruited from approximately 12 sites.

  RELATED STUDIES

• CTN-0030-A-1: Collection of Economic Data for the Prescription Opioid Addiction Treatment Study
• CTN-0030-A-2: Effects of Chronic Opioids on the Brain

	Find publications in the Library about Protocol CTN-0030